Get the Stockscreener App
28.40
0.18%
+0.05
After Hours:
28.40
Cullinan Oncology Inc stock is currently priced at $28.40, with a 24-hour trading volume of 765.73K.
It has seen a +0.18% increased in the last 24 hours and a +66.86% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $28.49 pivot point. If it approaches the $27.74 support level, significant changes may occur.
Previous Close:
$28.35
Open:
$28.4
24h Volume:
765.73K
Market Cap:
$1.22B
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-8.4273
EPS:
-3.37
Net Cash Flow:
$-134.48M
1W Performance:
+4.72%
1M Performance:
+66.86%
6M Performance:
+189.80%
1Y Performance:
+196.45%
1D Range:
$27.34
$28.85
52W Range:
$7.64
$29.25
Cullinan Oncology Inc Stock (CGEM) Company Profile
Name
Cullinan Oncology Inc
Sector
Industry
Phone
617-410-4650
Address
One Main Street, Suite 520, Cambridge
Cullinan Oncology Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Oncology Inc Stock (CGEM) Latest News
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
GlobeNewswire Inc.
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Benzinga
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
GlobeNewswire Inc.
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday
Benzinga
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Cullinan Oncology Inc Stock (CGEM) Financials Data
Cullinan Oncology Inc (CGEM) Net Income 2024
CGEM net income (TTM) was -$153.16 million for the quarter ending December 31, 2023, a -237.72% decrease year-over-year.
Cullinan Oncology Inc (CGEM) Cash Flow 2024
CGEM recorded a free cash flow (TTM) of -$134.48 million for the quarter ending December 31, 2023, a -5.23% decrease year-over-year.
Cullinan Oncology Inc (CGEM) Earnings per Share 2024
CGEM earnings per share (TTM) was -$3.69 for the quarter ending December 31, 2023, a -255.70% decline year-over-year.
About Cullinan Oncology Inc
Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell acute lymphoblastic leukemia; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. It has a collaboration agreement with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, LLC was founded in 2016 and is headquartered in Cambridge, Massachusetts.
0.41%
0.14%
Cap:
|
Volume (24h):